— Sacituzumab govitecan approved alone or in combination for first-line treatment
June 25, 2026
• 2 min read
The FDA approved sacituzumab govitecan (Trodelvy) for two indications in patients with metastatic triple-negative breast cancer (TNBC).
The first indication for the TROP2-targeting antibody-drug conjugate, supported by the ASCENT-03 trial, is for the first-line treatment of adults with unresectable locally advanced or metastatic disease who are not candidates for PD-1 or PD-L1 inhibitor-based therapy due to previous use or co-existing conditions.
